Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
ATX Stock Chart & Stats
AU$0.14
<AU$0.01(2.33%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(2.33%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.43
Previous CloseN/A
Volume274.48K
Average Volume (3M)525.22K
Market Cap
AU$87.22M
Enterprise ValueAU$58.45M
Total Cash (Recent Filing)AU$29.16M
Total Debt (Recent Filing)AU$381.42K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding513,071,660
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.02
Price to Sales (P/S)5.68
P/FCF Ratio-3.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsAmplia's ~90–100% gross margins reflect highly favorable unit economics typical of targeted therapeutics. Durable high gross profitability means incremental revenue can convert efficiently to gross profit, supporting long-term scalability and improved margins as fixed costs are leveraged.
Conservatively Levered Balance SheetMinimal debt and an extremely low debt-to-equity ratio reduce financial fragility and interest burden, giving management flexibility to fund development via partnerships or measured capital raises. This capital structure lowers bankruptcy risk and supports sustained R&D investment.
Partnership/licensing-driven Revenue ModelA business model focused on partnerships, licensing and milestone payments provides non-dilutive funding, strategic validation and commercialization pathways. These structural revenue streams can sustain development spending and de-risk programs versus sole internal funding.
Bears Say
Persistent And Rising Cash BurnOperating and free cash flow have been negative each year and cash burn grew in FY2025, eroding runway. Persistent, increasing outflows force reliance on external financing, heighten dilution risk, and constrain strategic flexibility over the medium term.
Deep, Sustained Operating LossesDespite revenue growth, Amplia remains deeply loss-making with large negative operating results and highly negative net margins. Sustained operating losses indicate the company is not yet at commercial scale and profitability depends on significant revenue expansion or material cost reduction.
Negative ROE And Uneven Equity GrowthPersistent negative returns on equity and a material equity dip in FY2024 (partial recovery in FY2025) signal erosion of shareholder value from ongoing losses and likely capital raises. Inconsistent equity growth undermines long-term return metrics and may reflect dilution risk.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$87.22M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 52 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $153.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-24.81%
Trailing 12-Months
Asset Growth
199.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Options Prices
Currently, No data available
---